LBLloyd Bod

Lloyd Bod

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lloyd Bod has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Armelle Prévost-Blondel

    INSERM, U1016, Institut Cochin, Paris, France

    7 shared publications
  • Renée Lengagne

    Institut National de la Santé et de la Recherche Médicale (INSERM), U1016, Institut Cochin, Paris, France

    6 shared publications
  • Laetitia Douguet

    Institut National de la Santé et de la Recherche Médicale (INSERM), U1016, Institut Cochin, Paris, France

    4 shared publications
  • Masashi Kato

    Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

    4 shared publications
  • Marie-Françoise Avril

    INSERM, U1016, Institut Cochin, Paris, France; CNRS, UMR8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; AP-HP, Service de Dermatologie, Hôpital Cochin, Paris, France

    3 shared publications
  • Valérie Molinier-Frenkel

    INSERM, U955, Equipe 09, Créteil, France; Université Paris Est, Faculté de Médecine, Créteil, France; AP-HP, Hôpital H. Mondor-A. Chenevier, Service d'Immunologie Biologique, Créteil, France

    3 shared publications

Latest Publications

  • Open Access

    Checkpoint Receptor TIGIT Expressed on Tim-1+ B Cells Regulates Tissue Inflammation

    by Sheng Xiao, Lloyd Bod, Nathalie Pochet, Savithri Balasubramanian Kota, Dan Hu, Asaf Madi, Jessica Kilpatrick, Jingwen Shi, Allen Ho, Huiyuan Zhang, et al.


  • Emerging Role of IL-4–Induced Gene 1 as a Prognostic Biomarker Affecting the Local T-Cell Response in Human Cutaneous Melanoma

    by Jan Philipp Ramspott, Fériel Bekkat, Lloyd Bod, Maryline Favier, Benoit Terris, Anne Salomon, Lounes Djerroudi, Kurt S. Zaenker, Yolande Richard, Valérie Molinier-Frenkel, et al.


  • Open Access

    Inflammation drives nitric oxide synthase 2 expression by γδ T cells and affects the balance between melanoma and vitiligo associated melanoma

    by Laetitia Douguet, Lloyd Bod, Laura Labarthe, Renée Lengagne, Masashi Kato, Isabelle Couillin, Armelle Prévost-Blondel

    The high expression of inducible nitric oxide synthase (NOS2) by myeloid-derived suppressor cells (MDSCs) is a key mechanism of immune evasion in cancer. Recently we reported that NOS2 is also expressed by γδ T cells in melanoma, contributing to their polarization towards a pro-tumor phenotype. The molecular mechanisms underlying regulation of NOS2 expression in tumor-induced γδ T cells remain unexplored. By using the model of mice transgenic for the ret oncogene (Ret mice) that develops a spontaneous metastatic melanoma, we evidence that interleukin (IL)-1β and IL-6 drive NOS2 expression in γδ T cells. Indeed, their in vivo neutralization lessens the γδ T cell capacity to produce not only NOS2, but also IL-17 involved in the recruitment of MDSCs at the primary tumor site. The treatment also delayed tumor cell dissemination and induced vitiligo in a significant proportion of Ret mice. Interestingly, Ret mice developing a less aggressive melanoma, characterized by the spontaneous development of a concomitant autoimmune vitiligo, exhibit a weaker concentration of inflammatory cytokines and a reduction of tumor infiltrating γδ T cells expressing NOS2, when compared to Ret mice without any signs of vitiligo. Overall our results support that the level of inflammation at the tumor site regulates NOS2 expression by γδ T cells and the development of vitiligo associated melanoma.


  • Open Access

    IL-4–Induced Gene 1: A Negative Immune Checkpoint Controlling B Cell Differentiation and Activation

    by Lloyd Bod, Laetitia Douguet, Cédric Auffray, Renée Lengagne, Fériel Bekkat, Elena Rondeau, Valérie Molinier-Frenkel, Flavia Castellano, Yolande Richard, Armelle Prévost-Blondel

    Emerging data highlight the crucial role of enzymes involved in amino acid metabolism in immune cell biology. IL-4–induced gene-1 (IL4I1), a secreted l-phenylalanine oxidase expressed by APCs, has been detected in B cells, yet its immunoregulatory role has only been explored on T cells. In this study, we show that IL4I1 regulates multiple steps in B cell physiology. Indeed, IL4I1 knockout mice exhibit an accelerated B cell egress from the bone marrow, resulting in the accumulation of peripheral follicular B cells. They also present a higher serum level of natural Igs and self-reactive Abs. We also demonstrate that IL4I1 produced by B cells themselves controls the germinal center reaction, plasma cell differentiation, and specific Ab production in response to T dependent Ags, SRBC, and NP-KLH. In vitro, IL4I1-deficient B cells proliferate more efficiently than their wild-type counterparts in response to BCR cross-linking. Moreover, the absence of IL4I1 increases activation of the Syk-Akt-S6kinase signaling pathway and calcium mobilization, and inhibits SHP-1 activity upon BCR engagement, thus supporting that IL4I1 negatively controls BCR-dependent activation. Overall, our study reveals a new perspective on IL4I1 as a key regulator of B cell biology.


  • Open Access

    IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma

    by Lloyd Bod, Renée Lengagne, Ludovic Wrobel, Jan Philipp Ramspott, Masashi Kato, Marie-Françoise Avril, Flavia Castellano, Valérie Molinier-Frenkel, Armelle Prévost-Blondel

    Amino acid catabolizing enzymes emerged as a crucial mechanism used by tumors to dampen immune responses. The L-phenylalanine oxidase IL-4 induced gene 1 (IL4I1) is expressed by tumor-associated myeloid cells of most solid tumors, including melanoma. We previously provided the only evidence that IL4I1 accelerates tumor growth by limiting the CD8+ T cell mediated immune response, in a mouse model of melanoma cell transplantation. Here, we explored the role of IL4I1 in Ret mice, a spontaneous model of melanoma. We found that IL4I1 was expressed by CD11b+ myeloid cells and that its activity correlated with disease aggressiveness. IL4I1 did not enhance tumor cell proliferation or angiogenesis, but orchestrated the remodeling of the immune compartment within the primary tumor. Indeed, the inactivation of IL4I1 limited the recruitment of polymorphonuclear myeloid-derived suppressor cells and enhanced the infiltration by Th1 and cytotoxic T cells, thus delaying tumor development and metastatic dissemination. Accordingly, human primary melanomas that were poorly infiltrated by IL4I1+ cells exhibited a higher density of CD8+ T cells. Collectively, our findings strengthen the rationale for therapeutic targeting of IL4I1 as one of the key immune regulators.


  • Open Access

    Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral γδ T Cells

    by Laetitia Douguet, Julien Cherfils-Vicini, Lloyd Bod, Renée Lengagne, Eric Gilson, Armelle Prévost-Blondel

    γδ T cells play critical roles in host defense against infections and cancer. Although advances have been made in identifying γδ TCR ligands, it remains essential to understand molecular mechanisms responsible for in vivo expansion of γδ T cells in periphery. Recent findings identified the expression of the inducible NO synthase (NOS2) in lymphoid cells and highlighted novel immunoregulatory functions of NOS2 in αβ T cell differentiation and B cell survival. In this context, we wondered whether NOS2 exerts an impact on γδ T cell properties. Here, we show that γδ T cells express NOS2 not only in vitro after TCR triggering, but also directly ex vivo. Nos2 deficient mice have fewer γδ T cells in peripheral lymph nodes (pLNs) than their wild-type counterparts, and these cells exhibit a reduced ability to produce IL-2. Using chemical NOS inhibitors and Nos2 deficient γδ T cells, we further evidence that the inactivation of endogenous NOS2 significantly reduced γδ T cell proliferation and glycolysis metabolism that can be restored in presence of exogenous IL-2. Collectively, we demonstrate the crucial role of endogenous NOS2 in promoting optimal IL-2 production, proliferation and glycolysis of γδ T cells that may contribute to their regulation at steady state.


  • Open Access

    Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma

    by Ludovic Jean Wrobel, Lloyd Bod, Renée Lengagne, Masashi Kato, Armelle Prévost-Blondel, Frédérique-Anne Le Gal

    Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma


  • Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma

    by Laetitia Douguet, Lloyd Bod, Renée Lengagne, Laura Labarthe, Masashi Kato, Marie-Françoise Avril, Armelle Prévost-Blondel

    γδ T lymphocytes may exert either protective or tumor-promoting functions in cancer, mostly based on their polarization toward interferon (IFN)-γ or interleukin (IL)-17 productions, respectively. Here, we demonstrate that γδ T cells accelerate the spontaneous metastatic melanoma development in a model of transgenic mice for the human RET oncogene (Ret mice). We identify unanticipated roles of inducible nitric oxide synthase (NOS2) in favoring the recruitment of pro-tumor γδ T cells within the primary tumor. γδ T cells isolated from Ret mice deficient for NOS2 produced more IFNγ and less IL-17 than their counterparts from Ret mice. By supporting IL-17 production by γδ T cells, NOS2 leads to the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and metastasis formation. NOS2 also reduces the cytotoxicity of γδ T cells toward melanoma cells. Finally, we detected NOS2 expressing γδ T cells in the primary tumor and tumor-draining lymph nodes in Ret mice, but also in human melanoma. Overall our results support that this NOS2 autocrine expression is responsible for the polarization of γδ T cells toward a pro-tumor profile.